BRPI1009461A8 - método não invasivo para avaliar a progressão da fibrose hepática - Google Patents

método não invasivo para avaliar a progressão da fibrose hepática

Info

Publication number
BRPI1009461A8
BRPI1009461A8 BRPI1009461A BRPI1009461A BRPI1009461A8 BR PI1009461 A8 BRPI1009461 A8 BR PI1009461A8 BR PI1009461 A BRPI1009461 A BR PI1009461A BR PI1009461 A BRPI1009461 A BR PI1009461A BR PI1009461 A8 BRPI1009461 A8 BR PI1009461A8
Authority
BR
Brazil
Prior art keywords
liver fibrosis
noninvasive method
assessing progression
assessing
progression
Prior art date
Application number
BRPI1009461A
Other languages
English (en)
Inventor
Cales Paul
Original Assignee
Centre Hospitalier Univ Dangers
Univ Angers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Univ Dangers, Univ Angers filed Critical Centre Hospitalier Univ Dangers
Publication of BRPI1009461A2 publication Critical patent/BRPI1009461A2/pt
Publication of BRPI1009461A8 publication Critical patent/BRPI1009461A8/pt
Publication of BRPI1009461B1 publication Critical patent/BRPI1009461B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4713Plasma globulins, lactoglobulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/495Transforming growth factor [TGF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7052Fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI1009461-0A 2009-03-19 2010-03-18 Métodos não invasivo para avaliar a progressão da fibrose hepática em um indivíduo e para avaliar se o indivíduo é formador de fibrose lenta, média ou rápida BRPI1009461B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16147409P 2009-03-19 2009-03-19
US61/161,474 2009-03-19
PCT/EP2010/053548 WO2010106140A1 (en) 2009-03-19 2010-03-18 Non-invasive method for assessing liver fibrosis progression

Publications (3)

Publication Number Publication Date
BRPI1009461A2 BRPI1009461A2 (pt) 2016-03-01
BRPI1009461A8 true BRPI1009461A8 (pt) 2017-09-12
BRPI1009461B1 BRPI1009461B1 (pt) 2019-08-20

Family

ID=42227782

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009461-0A BRPI1009461B1 (pt) 2009-03-19 2010-03-18 Métodos não invasivo para avaliar a progressão da fibrose hepática em um indivíduo e para avaliar se o indivíduo é formador de fibrose lenta, média ou rápida

Country Status (7)

Country Link
US (2) US20120010824A1 (pt)
EP (1) EP2409154B1 (pt)
JP (1) JP5612067B2 (pt)
CN (2) CN107014996A (pt)
BR (1) BRPI1009461B1 (pt)
ES (1) ES2644725T3 (pt)
WO (1) WO2010106140A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815416A1 (en) * 2010-10-21 2012-04-26 Vertex Pharmaceuticals Incorporated Biomarkers for hcv infected patients
US9036883B2 (en) * 2011-01-10 2015-05-19 The Regents Of The University Of Michigan System and methods for detecting liver disease
JP6193225B2 (ja) * 2011-06-29 2017-09-06 インナー モンゴリア フルイ メディカル サイエンス カンパニー リミテッドInner Mongolia Furui Medical Science Co., Ltd 肝線維症検出装置および検出システム
US9002656B2 (en) 2011-10-17 2015-04-07 Daxor Corporation Automated total body albumin analyzer
EP2873017B1 (en) 2012-07-11 2021-09-01 University of Mississippi Medical Center Method for the detection and staging of liver fibrosis from image acquired data
SG11201505294SA (en) * 2013-01-08 2015-08-28 Agency Science Tech & Res A method and system for assessing fibrosis in a tissue
EP2772882A1 (en) * 2013-03-01 2014-09-03 Universite D'angers Automatic measurement of lesions on medical images
EP2930515A1 (en) * 2014-04-08 2015-10-14 Universite D'angers Prognostic tests for hepatic disorders
CN105092855B (zh) * 2014-05-23 2017-10-03 杭州普望生物技术有限公司 一种用于肝纤维化和肝硬化检测的试剂盒
EP2980753A1 (en) 2014-08-01 2016-02-03 Centre Hospitalier Universitaire d'Angers Method for displaying easy-to-understand medical images
WO2016061621A1 (en) * 2014-10-21 2016-04-28 Jeffrey Gary Peter Liver test
CN104887243B (zh) * 2015-07-02 2017-08-01 郭璐 一种血小板指数测评快查计算滑动尺
EP3491388B1 (en) * 2016-08-01 2021-09-01 Centre Hospitalier Universitaire d'Angers Multi-targeted fibrosis tests
AU2018290511B2 (en) * 2017-06-26 2022-01-27 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and uses thereof in medicine
CN107368689B (zh) * 2017-07-31 2019-11-19 董云鹏 人体数据采集和分析系统
US12360113B2 (en) * 2017-10-16 2025-07-15 Biopredictive Method of prognosis and follow up of primary liver cancer
CN110237263B (zh) * 2018-03-07 2022-06-17 昆山新蕴达生物科技有限公司 HFn包载阿霉素的方法及其产物
CN108931645A (zh) * 2018-07-26 2018-12-04 北京大学第医院 一种hcv清除后肝纤维化评估系统及评估方法
CN109473175A (zh) * 2018-11-07 2019-03-15 中山大学附属第三医院(中山大学肝脏病医院) 一种针对肝纤维化的非侵入性血清学评分模型及其设计方法
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
TWI685854B (zh) 2019-02-01 2020-02-21 中國醫藥大學附設醫院 肝纖維化評估模型、肝纖維化評估系統及肝纖維化評估方法
BR112021023622A2 (pt) * 2019-05-24 2022-04-19 Assembly Biosciences Inc Composições farmaceuticas para o tratamento de hbv
CA3147038A1 (en) * 2019-07-12 2021-01-21 Primegen Biotech, Llc Methods of treatment using encapsulated cells
CA3171882A1 (en) * 2020-02-19 2021-08-26 Hepion Pharmaceuticals, Inc. Use of cyclosporine analogues for treating fibrosis
CN111783792B (zh) * 2020-05-31 2023-11-28 浙江大学 一种提取b超图像显著纹理特征的方法及其应用
CN112250769A (zh) * 2020-09-30 2021-01-22 四川携光生物技术有限公司 Ftcd和cyp2d6融合蛋白及其构建方法、应用
US12523658B2 (en) 2021-08-27 2026-01-13 The Board Of Regents Of The University Of Texas System Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications
JP2025538378A (ja) * 2022-11-11 2025-11-28 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 長期的肝線維症進行を予測するための分子シグネチャー

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141380B2 (en) 2000-04-28 2006-11-28 Michael Volker Assessment of liver fibrosis scoring with serum marker algorithms
US7668661B2 (en) * 2000-04-28 2010-02-23 Siemens Healthcare Diagnostics Inc. Liver disease-related methods and systems
GB0202213D0 (en) 2002-01-31 2002-03-20 Imp College Innovations Ltd Methods
US6986995B2 (en) 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
WO2006129513A1 (ja) 2005-05-30 2006-12-07 Ajinomoto Co., Inc. 肝疾患評価装置、肝疾患評価方法、肝疾患評価システム、肝疾患評価プログラムおよび記録媒体
JP4575354B2 (ja) 2003-01-14 2010-11-04 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) 肝線維症測定用血清マーカー
WO2005025596A1 (en) * 2003-09-16 2005-03-24 Hadasit Medical Research Services & Development Ltd. Glatiramer acetate for use as an immuno-modulatory agent
FR2870348B1 (fr) 2004-05-14 2010-08-27 Univ Angers Methode pour diagnostiquer la presence et/ou la severite d'une pathologie hepathique chez un sujet
JP2008506369A (ja) 2004-07-01 2008-03-06 メディカル リサーチ ファンド オブ テル アヴィヴ ソラスキー メディカル センター 慢性c型肝炎患者における肝臓線維化進行速度を予測するための方法およびキット
EP1626280B1 (en) * 2004-08-12 2007-02-14 Roche Diagnostics GmbH Method for diagnosing liver fibrosis
DE602006019262D1 (de) * 2005-08-11 2011-02-10 Siemens Healthcare Diagnostics QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
CA2689654A1 (en) * 2007-06-14 2008-12-18 Vib Vzw Diagnostic test for the detection of early stage liver cancer
US20100049029A1 (en) 2008-08-20 2010-02-25 Hong Kong Applied Science And Technology Research Institute Co., Ltd. Piezoelectric magnetic resonance elastograph (mre) driver system

Also Published As

Publication number Publication date
JP5612067B2 (ja) 2014-10-22
US20170337322A1 (en) 2017-11-23
WO2010106140A1 (en) 2010-09-23
BRPI1009461A2 (pt) 2016-03-01
EP2409154A1 (en) 2012-01-25
CN102439456A (zh) 2012-05-02
CN107014996A (zh) 2017-08-04
CN102439456B (zh) 2016-11-02
US10861582B2 (en) 2020-12-08
US20120010824A1 (en) 2012-01-12
JP2012520995A (ja) 2012-09-10
EP2409154B1 (en) 2017-08-02
ES2644725T3 (es) 2017-11-30
BRPI1009461B1 (pt) 2019-08-20

Similar Documents

Publication Publication Date Title
BRPI1009461A8 (pt) método não invasivo para avaliar a progressão da fibrose hepática
BR112013020220A2 (pt) métodos para determinação de ploidia pré-natal não invasiva
BRPI1015541A2 (pt) kit e método para a preparação de uma solução de degarelix
BRPI1013601A2 (pt) método para fabricação de uma emulsão de poliuretano reativa
BR112012000950A2 (pt) método e aparelho para fabricar um membro curvado
ES2858225T8 (es) Procedimiento para producir elementos estructurales templados
ME03396B (me) Oblici kisele soli konjugata polimer-lek
BR112013018900A2 (pt) conjuntos para uma estrutura
BRPI1013082A2 (pt) marcadores de risco para enfermidade cardiovascular
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BRPI1012638A2 (pt) métodos e intermediários para preparar agentes farmacêuticos
BR112012006620A2 (pt) método para fabricação de uma cobertura de engate de cilindro
BR112012031033A2 (pt) composição de si--g-poliolefina e processo para fazer uma composição de si-g-poliolefina
BR112013029498A8 (pt) método para produzir um suíno geneticamente modificado
BR112012016908A2 (pt) linhagens e métodos para a produção de metionina
BRPI0922490A2 (pt) Método para produção de beta-santaleno
BR112014000167A8 (pt) método para manufatura de uma casca de confeitaria
BR112012014162A2 (pt) método de fabricação de uma nanomanta
BR112013014479A2 (pt) método melhorado e kit para determinar a gravidade e progressão da doença periodontal
EP2781225A4 (en) TREATMENT AGENT FOR INTESTINAL FIBROSIS
BR112012021703A2 (pt) método e equipamento para a preparação de um novo lipossomo
BR112012010615A2 (pt) estrutura de colméia e método para formar uma estrutura de colméia
BR112013005986A2 (pt) processo para preparar uma composição derivada de estolídeo e composição derivada de estolídeo
BR112013015563A2 (pt) método para produzir uma amina terciária
BRPI1010841A2 (pt) método para a fabricação de fluoroalquilnitrilas

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2010, OBSERVADAS AS CONDICOES LEGAIS